CLAIMS

1. A compound selected from the specific group of compounds that comprises or consists of compounds of formula (I) or (II):

wherein:

R1 and R2 are joined to form a ring system; or

and R2 is 2-pyridin-4-yl-ethyl; 3-chloro-benzyl; R1 benzo[1,3]dioxol-4-ylmethyl; 4-sulfonamide-benzyl; benzyl; thiophen-2-ylmethyl; 1-phenyl-ethyl; 4-(4-amino-benzoylamino)phenyl; 4-methoxy-benzyl; 1-hydroxymethyl-2-methyl-propyl; 2-Pyridin-3-yl-ethyl; 4-phenoxy-phenyl;; 4-fluoro-phenyl; 4-[ethyl-(2hydroxy-ethyl)-amino]-phenyl; C1-C6 optionally substituted alkyl, eg including ethyl, propyl, 3-hydroxy-2,2-dimethyl-propyl, 3hydroxy-propyl, 2-methoxy-ethyl, 2-hydroxy-ethyl, 2hydroxymethyl-3-methyl-butyl, 1-hydroxymethyl-propyl, 2morpholin-4-yl-ethyl, furan-2-yl-methyl; C3-C6 substituted cycloalkyl eg including cyclohexane; 5 to 7 membered optionally substituted containing 1 to 3 heteroatoms selected from nitrogen and oxygen, preferably piperazine ring, [1,4]diazepane or a pyrrolidine ring; R2 is optionally linked to the scaffold by a linker which includes 1 to 3 carbon atoms;

R3 is benzofuran-2-yl; naphthalen-2-yl; 3-4-methoxy-phenyl; 4thiomethyl-phenyl; benzothiophen-2-yl; 4-pyridyl; 4-methoxyphenyl; quinolin-3-yl; benzo[1,3]dioxol-5-yl; 4-hydroxy-phenyl; 4-3-chloro-4-pyridyl; trifluoromethoxy-phenyl; 3-4-5-methoxyphenyl; 5-acetyl-thiophen-2-yl; 3-trifluoromethoxy-phenyl; hydroxymethyl-phenyl; N-(4-Methoxy-phenyl)-benzamide-4-yl; 3fluoro-4-chloro-phenyl; N-(2-Hydroxy-ethyl)-4- benzamide-4-yl; 3hydroxy-phenyl; 3-acetylamino-phenyl; quinolin-7-yl; 2-methoxy-5isopropyl-phenyl; 3-hydroxymethyl-phenyl; 3-pyridyl; hex-1-enyl; 4-cyano-phenyl; thiophen-3-yl; 3-nitro-phenyl; 3-chloro-phenyl; 2methoxy-phenyl; 4-isopropyl-phenyl;

R4 and R5 are joined to form a ring system; or

R4 is H or methyl; and R5 is 3-hydroxy-phenyl; 3-hydroxybenzoyl; 4-bromo-benzyl; 4-methoxybenzyl; 2,5-hydroxybenzyl; 3-hydroxy-4-methoxy-benzyl; 3-chloro-benzyl; 3-fluoro-4-chloro-benzyl; 3amino-benzyl; 3-trifluoromethoxy-benzyl; 4-hydroxy-benzyl; 4amino-benzyl; 1H-Indol-6-yl; 3-hydroxy-benzyl; naphthalen-2-ylmethyl; benzo[1,3]dioxol-4-ylmethyl; 3,4-fluoro-benzyl; 3,4-chlorobenzyl; furan-3-yl-methyl; 4-methoxy-phenyl; 4-chloro-benzyl; 3nitro-phenyl; 3,4-methoxy-phenyl; 3-bromo-phenyl; phenyl; phenyl; 3-chloro-phenyl; 2-naphtyl; pyridin-3-yl-methyl; pyridin-4-yl-methyl; quinolin-3-yl-methyl; 4-isopropyl-phenyl; 4chloro-benzyl; 3,4-methoxy-benzyl; 3-fluoro-4-chloro-phenyl; 4trifluoromethoxy-phenyl; 4-cyano-phenyl; 4-metoxy benzyl, 4methoxy-3-hydroxy benzyl; pyridin-4-yl-ethyl; piperidine-1carboxylic acid benzyl ester 3-yl-methyl; cyclohexane-methyl; 4chlorobenzoyl; pyrrolidine-2-yl-methyl; C1-C6 optionally substituted

alkyl, eg including ethyl, propyl, 3-hydroxy-2,2-dimethyl-propyl, 3-2-methoxy-ethyl, hydroxy-propyl, 2-hydroxy-ethyl, 2hydroxymethyl-3-methyl-butyl, 1-hydroxymethyl-propyl, 2morpholin-4-yl-ethyl, furan-2-yl-methyl; C5-C7 optionally substituted cycloalkyl eg including cyclohexane; 5 to 7 membered optionally substituted containing 1 to 3 heteroatoms selected from nitrogen and oxygen, eg including a piperazine ring, [1,4]diazepane or a pyrrolidine ring; and R5 is optionally linked to the scaffold by a linker which includes 1 to 3 carbon atoms;

R6 is 3-carbamoyl-phenyl; 4-hydroxy-phenyl; 4-amino-phenyl; 3amino-phenyl; phenyl; 1H-Indol-5-yl; 4-pyridyl; 3-hydoxy-phenyl; Benzo[1,3]dioxol-5-yl; 3-(2-Hydroxy-ethylcarbamoyl)-phenyl; hydroxymethyl-phenyl; 3-acetylamino-phenyl; 4-hydroxymethylphenyl; 3-(2-dimethylamino-ethylcarbamoyl)-phenyl; thiophene-3yl; 3-pyridyl; 3,4-methoxy-phenyl; 6-Bromo-1-carboxylic acid tertbutyl ester-indol-2-yl; 3-(2-hydroxy-ethylcarbamoyl)-phenyl; 3-Methanesulfonylamino-phenyl; 3-trifluoromethoxy-phenyl; hydroxymethyl-phenyl; 4-methanesulfonyl-phenyl; quinolin-3-yl; 5methoxy-pyridin-3-yl;4-carbamoyl-phenyl; 4-acetylamino-phenyl; 4-Methylcarbamoyl-phenyl; 4-(2-Hydroxy-ethylcarbamoyl)-phenyl; quinolin-4-yl; quinolin-5-yl; isoquinolin-4-yl; 1H-pyrazol-4-yl; 3chloro-pyridin-4-yl; 3-methoxy-pyridin-5-yl; 4-methoxy-pyridin-5or 2-methyl-pyridin-4-yl; benzothiophene-2-yl; 3-chloropyridine-4-yl; 1H-pyrazol-3-yl; isoquinolin-3-yl; 4-carbamoylphenyl; 4-carbamoyl-phenyl; 3-(2-Hydroxy-ethylcarbamoyl)-phenyl.

2. A compound according to claim 1, wherein R1 and R2 form a 5 to 7 membered ring optionally substituted containing 1 to 3 heteroatoms selected from nitrogen and oxygen.

- 3. A compound according to claim 2 wherein the ring is selected from 2-(2-hydroxy-ethyl)-piperidin-1-yl or 4-(2-hydroxy-ethyl)-piperazin-1-yl; 4-methyl-piperazin-1-yl; 4-pyridin-4-yl-piperazin-1-yl; 4-(2-dimethylamino-ethyl)-piperazin-1-yl; 4-(2-diethylamino-ethyl)-piperazin-1-yl; morpholin-4-yl; 4-(2-cyano-phenyl)-piperazin-1-yl; 4-methyl-[1,4]diazepan-1-yl; N-(2-dimethylamino-ethyl)-N-methyl-; 4-(3,4-dimethoxy-phenyl)-piperazin-1-yl; 4-pyridin-2-yl-piperazin-1-yl; 4-(2-hydroxy-ethyl)-piperazin-1-yl; 4-(furan-3-carbonyl)-piperazin-1-yl; 4-(2-pyrrolidin-1-yl-ethyl)-piperazin-1-yl; or 2-(2-hydroxy-ethyl)-pyrrolidin-1-yl.
- 4. A compound according to claim 1 wherein R4 and R5 form a 5 to 7 membered ring optionally substituted containing 1 to 3 heteroatoms selected from nitrogen and oxygen.
- 5. A compound according to claim 4 wherein the ring is selected from 2-(2-hydroxy-ethyl)-piperidin-1-yl or 4-(2-hydroxy-ethyl)-piperazin-1-yl; 4-methyl-piperazin-1-yl; 4-pyridin-4-yl-piperazin-1-yl; 4-(2-dimethylamino-ethyl)-piperazin-1-yl; 4-(2-diethylamino-ethyl)-piperazin-1-yl; morpholin-4-yl; 4-(2-cyano-phenyl)-piperazin-1-yl; 4-methyl-[1,4]diazepan-1-yl; N-(2-dimethylamino-ethyl)-N-methyl-; 4-(3,4-dimethoxy-phenyl)-piperazin-1-yl; 4-pyridin-2-yl-piperazin-1-yl; 4-(2-hydroxy-ethyl)-piperazin-1-yl; 4-(furan-3-carbonyl)-piperazin-1-yl; 4-(2-pyrrolidin-1-yl-ethyl)-piperazin-1-yl; or 2-(2-hydroxy-ethyl)-pyrrolidin-1-yl.
- 6. A compound according to claim 1, wherein:

R1 is hydrogen;

R2 is 2-pyridin-4-yl-ethyl; thiophen-2-ylmethyl; 4-sulfonamidebenzyl; or 3-chloro-benzyl; R3 is benzothiophen-2-yl; naphthalen-2-yl; 3-4-methoxy-phenyl; or 4-pyridyl;

R4 is hydrogen;

R5 is 3-hydroxy-benzyl; 4-chloro-benzyl; naphthalen-2-yl-methyl; benzo[1,3]dioxol-4-ylmethyl; 3,4-fluoro-benzyl; 3,4-chloro-benzyl; or furan-3-yl-methyl; and

R6 is 3-carbamoyl-phenyl; 4-hydroxy-phenyl; or 4-pyridyl.

- 7. A compound according to claim 1 that is selected from the group of compounds named in Table A or Table B.
- 8. A method for making a compound according to any one of claims 1 to 7, which method comprises at least one step or a series of consecutive steps from the scheme defined herein.
- 9. A group of two or more compounds comprising or consisting of a set of structurally related compounds having a core chemical structure (scaffold) of a general formula selected from the group consisting of formula I or II.
- 10. A group of two or more compounds according to claim 9 which comprises compounds according to any one of claims 1 to 7, and said group has all or substantially all of the permitted substitutions represented by compounds therein.
- 11. A method for making a group of compounds according to claim 10, which method comprises at least one step or a series of consecutive steps from the scheme defined herein.

- . 12. An assay comprising a group of compounds according to claim 9, or one or more compounds according to any one of claims 1 to 7.
 - 13. Use of an assay according to claim 12 for identifying a compound that has therapeutic affect.
 - 14. A pharmaceutical composition that comprises a compound according to any one of claims 1 to 7 or a compound identified in an assay according to claim 12.
 - 15. A compound according to any one of claims 1 to 7 for use in therapy.
 - 16. Use of a compound according to any one of claims 1 to 7 in the manufacture of a medicament for treatment or prophylaxis of a condition characterised by abnormal kinase activity.
 - 17. Use according to claim 16 wherein the medicament is for treatment or prophylaxis of a condition selected from cardiovascular disease (coronary vasospasm, hypertensive disease, arteriosclerosis), stroke, cancer, erectile dysfunction, asthma, osteoporosis, glaucoma and AIDS.
 - 18. A method of treatment of a condition characterised by abnormal kinase activity that comprises administering a pharmaceutically effective amount of a compound according to any one of claims 1 to 7.
 - 19. A method of treatment according to claim 18 wherein the condition is selected from cardiovascular disease (coronary vasospasm, hypertensive disease, arteriosclerosis), stroke, cancer, erectile dysfunction, asthma, osteoporosis. glaucoma and AIDS.

20. A compound, method of production, selection of compounds, assay, pharmaceutical composition, use or method of treatment substantially as described herein.